Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCB161734 |
Synonyms | |
Therapy Description |
INCB161734 selectively inhibits KRAS G12D, potentially resulting in decreased cell proliferation and tumor growth (Cancer Res (2024) 84 (6_Supplement): 5900). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB161734 | INCB-161734|INCB 161734 | KRAS G12D Inhibitor 16 | INCB161734 selectively inhibits KRAS G12D, potentially resulting in decreased cell proliferation and tumor growth (Cancer Res (2024) 84 (6_Supplement): 5900). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06179160 | Phase I | Cetuximab + INCB161734 + Retifanlimab INCB161734 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | AUS | 1 |